Nautilus Biotechnology Inc (NASDAQ:NAUT) price on Thursday, March 28, rose 6.14% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.94.
A look at the stock’s price movement, the close in the last trading session was $2.77. The beta value (5-Year monthly) was 1.01. Turning to its 52-week performance, $4.65 and $2.16 were the 52-week high and 52-week low respectively. Overall, NAUT moved 5.00% over the past month.
Nautilus Biotechnology Inc’s market cap currently stands at around $367.79 million, with investors looking forward to this quarter’s earnings report slated for Feb 28, 2024. Analysts project the company’s earnings per share (EPS) to be -$0.16, which has seen fiscal year 2024 EPS growth forecast to increase to -$0.74 and about -$0.83 for fiscal year 2025. Per the data, EPS growth is expected to be -45.10% for 2024 and -12.20% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that NAUT is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
NAUT’s current price about 10.22% and 5.47% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.85, while 7-day volatility ratio is 6.56% and 7.93% in the 30-day chart. Further, Nautilus Biotechnology Inc (NAUT) has a beta value of 0.99, and an average true range (ATR) of 0.20.
If we refocus on Nautilus Biotechnology Inc (NASDAQ:NAUT), historical trading data shows that trading volumes averaged 80300.0 over the past 10 days and 84.45K over the past 3 months. The company’s latest data on shares outstanding shows there are 125.07 million shares.
The 54.48% of Nautilus Biotechnology Inc’s shares are in the hands of company insiders while institutional holders own 28.90% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.23 million on Mar 15, 2024, giving us a short ratio of 12.68. The data shows that as of Mar 15, 2024 short interest in Nautilus Biotechnology Inc (NAUT) stood at 0.99% of shares outstanding. Current price change has pushed the stock -1.67% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NAUT stock continues to rise going into the next quarter.
